Cormorant Asset Management liquidates ~10% stake in Bright Minds Biosciences for ~$9.8M as stock rallies near highs.
Cormorant Asset Management, a large shareholder holding ten percent of Bright Minds Biosciences, sold roughly a tenth of its position shortly after the stock rallied sharply. The timing is notable: the stock has recovered strongly over recent weeks and is now trading just below its 52-week highs, yet the fund chose to exit a material portion of its holdings at these elevated levels rather than hold through. This is institutional portfolio management rather than insider knowledge-driven selling—Cormorant is rebalancing its position, not flagging internal concerns. However, the size of the sale ($9.8M) and the decision to reduce exposure near all-time prices suggests the fund may view current valuations as an attractive exit opportunity after strong momentum. For retail investors, this is a neutral signal: it reflects fund capital allocation, not management confidence or distress.